The good, the bad, and the totally bad: lessons from 25 years building biotech companies
Ned is a biochemist and drug hunter who co-founded Jupiter, a biotech foundry that turns early science into new biotech companies.
Ned will review his 25 years of biotech company building: what went right (i.e., approved medicines with great investor returns) and what went spectacularly, phantasmagorically wrong (e.g., imagine smoldering craters of vaporized venture capital). Ned will also discuss the Jupiter model of company creation as one way to tackle audacious biotech projects while thoughtfully managing risk.
Our Speaker
Nathaniel “Ned” David, PhD
Before co-founding Jupiter, Ned co-founded four companies, three of which went public on NASDAQ while one was acquired: Kythera Biopharmaceuticals (NASDAQ: KYTH, later acquired by Allergan), Achaogen (NASDAQ: AKAO), UNITY Biotechnology (NASDAQ: UBX), and Syrrx (acquired by Takeda), companies that together created four approved medicines (ALOGLIPTIN, TRELAGLIPTIN, ZEMDRI, and KYBELLA).
Ned earned his PhD in Molecular and Cellular Biology from UC Berkeley, his AB in Biology from Harvard College, and is an inventor on 70 allowed patents.
He likes baking and Bach.